Compare RCAT & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | TRAX |
|---|---|---|
| Founded | 2002 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2017 | 2026 |
| Metric | RCAT | TRAX |
|---|---|---|
| Price | $5.80 | $31.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $16.50 | ★ $70.58 |
| AVG Volume (30 Days) | ★ 6.6M | 604.3K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,836,382.00 | N/A |
| Revenue This Year | $270.70 | N/A |
| Revenue Next Year | $45.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $5.77 | $15.69 |
| 52 Week High | $18.78 | $49.91 |
| Indicator | RCAT | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 23.62 | 35.27 |
| Support Level | N/A | $15.69 |
| Resistance Level | $11.75 | $48.94 |
| Average True Range (ATR) | 0.24 | 2.55 |
| MACD | -0.01 | -0.43 |
| Stochastic Oscillator | 4.92 | 9.46 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.